经动脉灌注化疗与经动脉化疗栓塞治疗不可切除肝细胞癌患者的疗效比较：一项系统评价和荟萃分析。
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
机构信息
Department of Interventional Therapy, Affiliated Hospital of Qinghai University, Xining, China.
Department of Postgraduate, Qinghai University, Xining, China.
出版信息
Acta Clin Belg. 2023 Apr;78(2):171-179. doi: 10.1080/17843286.2022.2076791. Epub 2022 May 19.
BACKGROUND
We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC).
METHODS
Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR).
RESULTS
Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81-0.98), HR = 0.84 (95% CI, 0.75-0.93), OR = 2.77 (95% CI, 2.01-3.80), and OR = 4.64 (95% CI, 2.40-8.99), respectively. The adverse events of HAIC were lower than TACE.
CONCLUSION
Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.
背景
我们进行了一项系统评价和荟萃分析，以评估与经动脉化疗栓塞（TACE）相比，肝动脉灌注化疗（HAIC）治疗不可切除肝细胞癌（uHCC）患者的安全性和有效性。
方法
通过 MEDLINE、Cochrane 图书馆、Embase 和 Web of Science 从 1995 年 1 月到 2022 年 1 月搜索了符合条件的研究，调查了比较 HAIC 和 TACE 治疗 HCC 患者的合格文献。主要观察指标包括无进展生存期（PFS）、总生存期（OS）、不良事件（AEs）、客观缓解率（ORR）和疾病控制率（DCR）。
结果
本荟萃分析纳入了 8 篇文献和 1028 例患者。荟萃分析的 PFS、OS、ORR 和 DCR 的合并 HR 分别为 0.89（95%CI，0.81-0.98）、HR 为 0.84（95%CI，0.75-0.93）、OR 为 2.77（95%CI，2.01-3.80）和 OR 为 4.64（95%CI，2.40-8.99）。HAIC 的不良事件发生率低于 TACE。
结论
我们的荟萃分析表明，与 TACE 相比，HAIC 可在 uHCC 患者中获得更好的疗效和生存获益。
Zotero 插件